| 前收市價 | 282.89 |
| 開市 | 285.20 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 285.20 - 288.90 |
| 52 週波幅 | 252.87 - 334.30 |
| 成交量 | |
| 平均成交量 | 1,982 |
| 市值 | 231.842B |
| Beta 值 (5 年，每月) | 0.19 |
| 市盈率 (最近 12 個月) | 18.30 |
| 每股盈利 (最近 12 個月) | 15.79 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 10.25 (3.62%) |
| 除息日 | 2023年3月16日 |
| 1 年預測目標價 | 無 |
- Financial Times
Roche: fat fighter drugs buy must precede trial wins
Novo Nordisk and Eli Lilly are already striding ahead with anti-obesity treatments. Switzerland’s Roche has just boosted its chances of being a contender. It is acquiring US-based obesity drugs developer Carmot Therapeutics for up to $3.1bn.
- Financial Times
Roche to buy Carmot for up to $3.1bn as race for obesity drugs intensifies
Roche has agreed to buy anti-obesity drug developer Carmot Therapeutics for up to $3.1bn, as the Swiss pharmaceutical group joins the industry’s charge into the fast-growing market for weight loss treatments. The acquisition of Carmot, which is based in Berkeley, California, hands Roche a series of assets based on glucagon-like peptide 1 (GLP-1) agonists, which were developed to help control blood sugar levels in people with diabetes. GLP-1s now underpin a weight loss drug, Wegovy, developed by pharmaceutical group Novo Nordisk.
Insider MonkeyLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript November 9, 2023 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.05. Operator: Welcome to the Lineage Cell Therapeutics Third Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call […]
